PLoS ONE · 2018 · 66 citations · 17 references
MedicineImmunologyPathologyClinical ImmunologyImmunopathologyPulmonologyImmune-mediated Inflammatory DiseasesInterstitial Lung DiseasePulmonary InflammationPulmonary PathologyAnti-myeloperoxidase AntibodiesAnti-neutrophil Cytoplasmic AntibodiesAnti-neutrophil Cytoplasmic Antibody TestingInterstitital Lung DiseasePulmonary Fibrosis Progression
OBJECTIVE: Although a possible association among myeloperoxidase-anti-neutrophil cytoplasmic antibody (MPO-ANCA), microscopic polyangiitis (MPA), and idiopathic pulmonary fibrosis (IPF) has been suggested, the clinical significance of MPO-ANCA in idiopathic interstitial pneumonias (IIPs), including IPF and non-IPF, remains unclear. We aimed to investigate the frequency of MPO-ANCA positivity, as well as MPA incidence and risk factors for development in patients initially diagnosed with IIP. METHODS: We retrospectively analysed 305 consecutive patients who were initially diagnosed as IIP and had MPO-ANCA results available. RESULTS: Of the 305 patients, 26 (8.5%) were MPO-ANCA-positive. Baseline characteristics were similar between the MPO-ANCA-positive and -negative patients. The cumulative 5-year MPA incidence was 24.3% in the MPO-ANCA-positive patients and 0% in the -negative patients (P < 0.0001). MPO-ANCA was positive in 15 of 133 (11.3%) patients initially diagnosed with IPF and in 11 of 172 (6.3%) patients initially diagnosed with non-IPF (P = 0.56), with cumulative 5-year MPA incidence of 6.2% and 1.0%, respectively (P = 0.10). Multivariate analysis revealed that UIP pattern on HRCT (HR = 3.20, P < 0.01) and no treatment for IIP (HR = 3.52, P < 0.01) were independently associated with MPA development in MPO-ANCA-positive patients. CONCLUSION: MPO-ANCA positivity was uncommon, but was associated with subsequent MPA development in patients initially diagnosed with IIP, including both IPF and non-IPF cases. The study suggested that attention should be paid to MPA development in MPO-ANCA-positive IIP patients with UIP pattern on HRCT and those without treatment for IIP.
17
Ganesh Raghu, Harold R. Collard, Jim Egan et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 7.3K citations · Full text
William D. Travis, Ulrich Costabel, David M. Hansell et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 4.3K citations · Full text
Richard Watts, Suzanne Lane, Thomas Hanslik et al. · Annals of the Rheumatic Diseases · 2006 · 1.4K citations · Full text
Life Sciences, Immunology, Clinical Classification Systems +11